Home > Insider Trading > Filing (0000950170-23-018401)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1840229	Mink Therapeutics Inc.	INKT	Biological Products, (No Disgnostic Substances) (2836)	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1098972	Agenus Inc	3 Forbes Road Lexington MA 02421		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-05-03	128,689	$1.08	21,473,374	No	4	P	Direct
Common Stock	Acquisiton	2023-05-04	21,473	$1.22	21,494,847	No	4	P	Direct
Common Stock	Acquisiton	2023-05-05	100,000	$0.95	21,594,847	No	4	P	Direct
Common Stock	Acquisiton	2023-05-05	200	$1.25	21,595,047	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $0.9144 to $1.20).
Agenus Inc. undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
Open market purchases reported on this line occurred at a weighted average price of $1.0789 (range of $1.20 to $1.25).
On May 5, 2023, Agenus purchased 100,000 shares of MiNk Therapeutics, Inc. common stock from Garo Armen, Agenus's Chairman and CEO, at the same price he paid to acquire the shares on May 2, 2023. The acquisition price represents a 40% discount to the market price as of today's market close.